NO20083640L - Antistoff-formulering - Google Patents

Antistoff-formulering

Info

Publication number
NO20083640L
NO20083640L NO20083640A NO20083640A NO20083640L NO 20083640 L NO20083640 L NO 20083640L NO 20083640 A NO20083640 A NO 20083640A NO 20083640 A NO20083640 A NO 20083640A NO 20083640 L NO20083640 L NO 20083640L
Authority
NO
Norway
Prior art keywords
antibodies
formulations
freeze
stabilizing
vegfr
Prior art date
Application number
NO20083640A
Other languages
English (en)
Norwegian (no)
Inventor
Joel Goldstein
Arvind Srivastava
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of NO20083640L publication Critical patent/NO20083640L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20083640A 2006-02-15 2008-08-22 Antistoff-formulering NO20083640L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77410106P 2006-02-15 2006-02-15
PCT/US2007/004050 WO2007095337A2 (en) 2006-02-15 2007-02-15 Antibody formulation

Publications (1)

Publication Number Publication Date
NO20083640L true NO20083640L (no) 2008-11-17

Family

ID=38372139

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083640A NO20083640L (no) 2006-02-15 2008-08-22 Antistoff-formulering

Country Status (13)

Country Link
US (1) US20090306348A1 (pt)
EP (1) EP1987067A4 (pt)
JP (1) JP2009526856A (pt)
KR (1) KR20080096827A (pt)
CN (1) CN101495136A (pt)
AU (1) AU2007215012A1 (pt)
BR (1) BRPI0707796A2 (pt)
CA (1) CA2642270A1 (pt)
EA (1) EA200870264A1 (pt)
IL (1) IL193408A0 (pt)
MX (1) MX2008010562A (pt)
NO (1) NO20083640L (pt)
WO (1) WO2007095337A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654794A1 (en) * 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2738243C (en) 2008-10-29 2020-09-29 Wyeth Llc Formulations of single domain antigen binding molecules
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011121301A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd Excipients for stabilising viral particles, polypeptides or biological material
CA2795050C (en) * 2010-03-31 2018-05-22 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
ES2757591T3 (es) 2010-03-31 2020-04-29 Stabilitech Biopharma Ltd Estabilización de partículas virales
EP2625203A1 (en) 2010-10-05 2013-08-14 Novartis AG Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
TWI486617B (zh) * 2010-10-21 2015-06-01 Iner Aec Executive Yuan 一種測定對鎝（Ｔｃ－９９ｍ）與錸（Ｒｅ－１８６、Ｒｅ－１８８）具有穩定錯合力之含硫螯合劑在凍晶劑中之含量與均一性的固態樣品分析技術
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
JP2014534265A (ja) * 2011-11-28 2014-12-18 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド インスリンアミノ酸配列を含む治療薬
CA2868883C (en) * 2012-03-30 2022-10-04 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
US9029510B2 (en) 2012-03-30 2015-05-12 Sorrento Therapeutics, Inc. Fully human antibodies that bind to VEGFR2 and methods of use thereof
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
LT2953969T (lt) 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
WO2017122130A1 (en) 2016-01-11 2017-07-20 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
CN106188296B (zh) * 2016-07-19 2018-05-08 康融东方（广东）医药有限公司 一类抗血管内皮生长因子受体vegfr2的单克隆抗体及其编码基因和应用
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
US20200255496A1 (en) * 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN110646618B (zh) * 2019-09-17 2022-11-01 广州市伊川生物科技有限公司 一种c反应蛋白测定试剂盒及其制备方法和应用
CA3169959A1 (en) * 2020-02-21 2021-08-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-il-4r antibody and use thereof
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
MXPA04000747A (es) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Formulacion farmaceutica liofilizada estable de anticuerpos igg.
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂

Also Published As

Publication number Publication date
EA200870264A1 (ru) 2009-02-27
EP1987067A2 (en) 2008-11-05
WO2007095337A3 (en) 2008-11-27
CA2642270A1 (en) 2007-08-23
KR20080096827A (ko) 2008-11-03
AU2007215012A1 (en) 2007-08-23
EP1987067A4 (en) 2012-01-25
MX2008010562A (es) 2009-03-05
BRPI0707796A2 (pt) 2011-05-10
IL193408A0 (en) 2011-08-01
US20090306348A1 (en) 2009-12-10
WO2007095337A2 (en) 2007-08-23
JP2009526856A (ja) 2009-07-23
CN101495136A (zh) 2009-07-29

Similar Documents

Publication Publication Date Title
NO20083640L (no) Antistoff-formulering
WO2008116103A3 (en) Stable antibody formulations
WO2012076670A3 (en) Antibody formulation
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
WO2010100200A3 (en) Lyophilised antibody formulation
EP4249512A3 (en) Stable antibody formulation
MY159156A (en) Antibody formulation
TW200744665A (en) Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
NO20064584L (no) Tetrahydropyridoindolderivater
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
MX360435B (es) Formulaciones farmaceuticas muy concentradas.
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007056220A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
WO2010078036A3 (en) Biocompatible polysaccharide-based hydrogels
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
WO2009045700A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
MY209656A (en) Compositions and methods of enhancing 5-hydroxytryptophan bioavailability
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

FC2A Withdrawal, rejection or dismissal of laid open patent application